Literature DB >> 2463877

Mechanism of reversion of Rous sarcoma virus transformation by herbimycin A: reduction of total phosphotyrosine levels due to reduced kinase activity and increased turnover of p60v-src1.

Y Uehara1, Y Murakami, Y Sugimoto, S Mizuno.   

Abstract

We studied the mechanism of reversion of Rous sarcoma virus (RSV)-transformation by herbimycin A in a temperature-sensitive RSV-infected NRK cell line. Herbimycin reduced the total cellular phosphotyrosine level to 10% of the control value. Intracellular p60src kinase activity was reduced significantly within 3 h of herbimycin treatment, but recovered to approximately 50% of the control within 24 h, and the kinetics paralleled the decrease of the phosphorylation of a cellular target p36. Partial proteolytic phosphopeptide analysis of p60src revealed decreased phosphorylation of tyrosine 416 in the C-terminal half. Analysis of the steady state level of p60src indicated 30% decrease in src protein. Measurement of the rates of p60src synthesis and degradation showed that the decrease in the level was due to the accelerated degradation of src protein. Cycloheximide blocked this enhanced turnover of p60src, but did not block the herbimycin-induced inactivation of p60src kinase. Subcellular distribution and myristoylation of p60src protein were not altered. These results support the idea that RSV transformation is associated with elevated phosphotyrosine levels and indicate that inhibition of src kinase activity can reverse RSV-transformation by reducing cellular phosphotyrosine content.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2463877

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  26 in total

Review 1.  Macrocyclic inhibitors of hsp90.

Authors:  Victoria A Johnson; Erinprit K Singh; Lidia A Nazarova; Leslie D Alexander; Shelli R McAlpine
Journal:  Curr Top Med Chem       Date:  2010       Impact factor: 3.295

Review 2.  Thom Award Lecture. Trends in the search for bioactive microbial metabolites.

Authors:  S Omura
Journal:  J Ind Microbiol       Date:  1992-09

3.  Intestinal HT-29 cells with dysfunction of E-cadherin show increased pp60src activity and tyrosine phosphorylation of p120-catenin.

Authors:  A Skoudy; M D Llosas; A García de Herreros
Journal:  Biochem J       Date:  1996-07-01       Impact factor: 3.857

4.  Separation of oxidant-initiated and redox-regulated steps in the NF-kappa B signal transduction pathway.

Authors:  M T Anderson; F J Staal; C Gitler; L A Herzenberg; L A Herzenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1994-11-22       Impact factor: 11.205

5.  Beta 2-integrin LFA-1 signaling through phospholipase C-gamma 1 activation.

Authors:  S B Kanner; L S Grosmaire; J A Ledbetter; N K Damle
Journal:  Proc Natl Acad Sci U S A       Date:  1993-08-01       Impact factor: 11.205

6.  Transformation of Rat-1 fibroblasts with the v-src oncogene increases the tyrosine phosphorylation state and activity of the alpha subunit of Gq/G11.

Authors:  W W Liu; R R Mattingly; J C Garrison
Journal:  Proc Natl Acad Sci U S A       Date:  1996-08-06       Impact factor: 11.205

7.  Association of muscle-specific kinase MuSK with the acetylcholine receptor in mammalian muscle.

Authors:  C Fuhrer; J E Sugiyama; R G Taylor; Z W Hall
Journal:  EMBO J       Date:  1997-08-15       Impact factor: 11.598

8.  Conversion of epidermal growth factor (EGF) into a stimulatory ligand for A431-cell growth by herbimycin A by decreasing the level of expression of EGF receptor.

Authors:  Y Murakami; H Fukazawa; S Mizuno; Y Uehara
Journal:  Biochem J       Date:  1994-07-01       Impact factor: 3.857

9.  Accelerated degradation of 160 kDa epidermal growth factor (EGF) receptor precursor by the tyrosine kinase inhibitor herbimycin A in the endoplasmic reticulum of A431 human epidermoid carcinoma cells.

Authors:  Y Murakami; S Mizuno; Y Uehara
Journal:  Biochem J       Date:  1994-07-01       Impact factor: 3.857

10.  Inhibitory effect of tyrphostin on the replication of herpes simplex virus type 1.

Authors:  Y Yura; J Kusaka; Y Kondo; H Tsujimoto; H Yoshida; M Sato
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.